No replies to this topic

[Phlogiston]

Bron: https://www.frontier...he-21st-century

 

Overview
Basic science research with psychedelic drugs continued relatively unabated after the cessation of clinical work with these compounds in 1970. Studies with the “classic psychedelics”, whose most well-known representative is LSD, have been responsible for fundamental discoveries in neuropsychopharmacology, in particular within the field of serotonin and, more recently, the sigma-1 complex. New generations of antidepressants, antipsychotics, and anxiolytics have followed on the heels of the increasingly refined understanding of the serotonergic neuronal systems afforded by research with the psychedelics. The resumption of human research with these compounds in the late 1980s affords the opportunity to confirm and extend preclinical discoveries, as well as direct studies into exclusively clinical domains. Now, in the 21st century, psychedelic drug research is undergoing a rapidly expanding resurgence at all levels, from the most basic biochemistry of drug-receptor interactions, to efficacy as agents for psychotherapy, as well as enhancement of normal function.

This Research Topic will bring together a selection of primary research, review, and opinion. It will welcome contributions from all levels and across all the major disciplines actively involved in psychedelic drug research.

We welcome contributions from basic molecular and pharmacological science, focusing on drug-receptor interactions and their functional impact, as well as the effects of psychedelic drugs on neural systems. From this fundamental level, the scope will reach into the clinical counterparts of brain imaging and clinical neuropsychopharmacological findings. Psychological effects in normal volunteers will also be represented, in addition to the relevance of psychedelic drug states as models for psychopathology. Finally, we will consider the application of the psychedelic drug effect to various clinical conditions, both psychopathological as well as directed towards the enhancement of normal function. These include psychotherapy for usually intractable psychiatric diagnoses, enhancement of creativity, and the nascent field of “clinical spirituality.”

 

1. Ayahuasca and its DMT- and ß-carbolines- containing ingredients block the expression of ethanol-induced conditioned place preference in mice: role of the treatment environment

 

2. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes

 

3. Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum

 

4. Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile

 

5. Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

 

6. Indolethylamine-N-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine

 

7. Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process

 

8. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy

 

9. Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program

 

10. Metabotropic Glutamate₂ Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice

 

11. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study

 

12. The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity

 

13. Unifying Theories of Psychedelic Drug Effects

 

14. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics

 

15. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions

 

16. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

 

17. β₂-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate

 

18. Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice

 

19. The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports

 

20. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

 

21. LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation

 

22. The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology

 

23. MDMA-Induced Dissociative State not Mediated by the 5-HT_2A Receptor

 

24. A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects